MTOR (mechanistic target of rapamycin kinase; HGNC:3942, NCBI Gene ID 2475) is a human locus mapped to chromosome band 1p36.22 that encodes PI3K-related serine/threonine kinase mTOR (2,549 aa; 289 kDa; catalytic core of mTORC1 & mTORC2; EC 2.7.11.1). MTOR acts in amino-acid (leucine/arginine Rag-GTPase) & insulin/IGF1-AKT1 sensing -> S6K1/4E-BP1 protein synthesis & ULK1/TFEB autophagy suppression, together with AMPK (Catabolic Energy Sensor That Inhibits mTORC1), AKT1 (Upstream Insulin/IGF-1 Kinase Activating mTORC1), and PTEN (Tumor Suppressor Antagonizing PI3K-AKT-mTOR). Mechanistic target of rapamycin, the master nutrient-sensing kinase complex governing cell growth, protein synthesis, autophagy, and aging.
Gain-of-function causes focal cortical dysplasia & Smith-Kingsmore syndrome; inhibition by rapamycin (sirolimus/everolimus) is the most conserved pharmacological lifespan extension
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 58-exon gene spanning 156 kb at chromosome 1p36.22, encoding a 2,549-amino-acid PIKK family serine/threonine kinase containing N-terminal HEAT repeats (which bind Raptor in mTORC1 or Rictor in mTORC2), a FAT domain, the FKBP12-rapamycin-binding (FRB) domain, the catalytic kinase domain, and a C-terminal FATC domain.
Cellular & Tissue Expression Profile: Ubiquitously expressed in all eukaryotic cells, shuttling as mTOR Complex 1 (mTORC1: mTOR, Raptor, mLST8, PRAS40, DEPTOR) to the cytosolic surface of the lysosomal membrane when amino acids are abundant.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Integrates dual coincidence detection at the lysosome: dietary amino acids (leucine sensed by Sestrin2, arginine by CASTOR1/SLC38A9) activate RagA/B-RagC/D heterodimeric GTPases to tether mTORC1 to the lysosomal surface, where insulin/IGF-1-PI3K-AKT1 signaling inhibits the TSC1-TSC2 complex so Rheb-GTP can allosterically activate the mTOR kinase cleft; active mTORC1 phosphorylates S6K1 and 4E-BP1 to drive cap-dependent mRNA translation, activates SREBP-1/2 lipogenesis and HIF1A/ATF4 nucleotide synthesis, and phosphorylates ULK1 (at Ser757) and TFEB to potently suppress macroautophagy and lysosomal biogenesis (directly opposed by AMPK).
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Somatic or germline mosaic gain-of-function missense mutations in MTOR cause focal cortical dysplasia type II with intractable epilepsy and Smith-Kingsmore overgrowth-macrocephaly syndrome; across yeast, C. elegans, Drosophila, and genetically heterogeneous mice (NIH Intervention Testing Program), genetic or pharmacological attenuation of mTORC1 is the single most reproducible intervention that extends median and maximal eukaryotic lifespan.
Therapeutic & Clinical Pharmacology: Allosterically inhibited via FKBP12 complex formation at the FRB domain by rapamycin (sirolimus) and rapalogs (everolimus, temsirolimus)—FDA-approved for organ transplant immunosuppression, renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex—and evaluated at intermittent low doses in geroscience clinical trials to enhance elderly immune response and proteostasis.